Otonomy, Inc. (OTIC): Price and Financial Metrics
OTIC Stock Summary
- OTIC's price/sales ratio is 394.69; that's higher than the P/S ratio of 98.33% of US stocks.
- As for revenue growth, note that OTIC's revenue has grown -54.5% over the past 12 months; that beats the revenue growth of only 5.19% of US companies in our set.
- Otonomy Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -60.01%, greater than the shareholder yield of only 3.67% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Otonomy Inc are SRRA, CLLS, EVGN, RARE, and KLDO.
- Visit OTIC's SEC page to see the company's official filings. To visit the company's web site, go to www.otonomy.com.
OTIC Stock Price Chart Interactive Chart >
OTIC Price/Volume Stats
|Current price||$2.25||52-week high||$6.98|
|Prev. close||$2.23||52-week low||$1.95|
|Day high||$2.25||Avg. volume||1,122,046|
|50-day MA||$3.44||Dividend yield||N/A|
|200-day MA||$4.07||Market Cap||108.72M|
Otonomy, Inc. (OTIC) Company Bio
Otonomy Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. The company was founded in 2008 and is based in San Diego, California.
OTIC Latest News Stream
|Loading, please wait...|
OTIC Latest Social Stream
View Full OTIC Social Stream
Latest OTIC News From Around the Web
Below are the latest news stories about Otonomy Inc that investors may wish to consider to help them evaluate OTIC as an investment opportunity.
Otonomy (OTIC) has priced its public offering of ~6.3M common shares at $2.25/share and, pre-funded warrants to purchase up to ~7.1M shares at $2.249/pre-funded warrant.Expected gross are ~$30.1M.Underwriters' over-allotment is an additional 2.01M shares. Cowen and Piper Sandler are acting as joint book-running managers.Closing date is April 12.Shares down 7.4% after-hours. Yesterday's...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to the public of $2.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,111,110 shares of its common stock at a purchase price of $2.249 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $30.1 million, before deducting underwriti...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. Otonomy may, in lieu of common stock, offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in the underwritten public offering. In addition, Otonomy expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in this public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when...
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the 20th Annual Needham Virtual Healthcare Conference. David A. Weber, Ph.D., president and CEO of Otonomy, will present a company overview on Tuesday, April 13, 2021 at 4:30 p.m. ET (1:30 p.m. PT). A live audio webcast of the presentation will be available through the Events page of the company's website (www.otonomy.com). An archived webcast of the presentation will also be available on the same web page shortly after the live event. About OtonomyOtonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pionee...
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at the upcoming American Neurotology Society’s 56th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose & Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial. “We are pleased to have the opportunity to present clinical results from the OTO-3...
OTIC Price Returns
Continue Researching OTICWant to do more research on Otonomy Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!